Boston Scientific (BSX) Non-Current Deferred Tax Liability (2009 - 2026)

Boston Scientific has reported Non-Current Deferred Tax Liability for 18 years, with the latest figure at $221.0 million in Q2 2026.

• Non-Current Deferred Tax Liability for Q2 2026 came in at $221.0 million, down 2.21% year-over-year; the trailing twelve-month figure through Jun 2026 was $221.0 million (down 2.21% YoY), and the FY2025 annual result was $220.0 million, down 0.9% from the prior year.
• Non-Current Deferred Tax Liability climbed to $221.0 million in Q2 2026, from $219.0 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $278.0 million in Q3 2022 and troughed at $91.0 million in Q3 2023.
• A 5-year average of $190.8 million and a median of $214.5 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• The widest annual swing landed in 2022, when Non-Current Deferred Tax Liability jumped 130.43%; it then slumped 67.27% in 2023.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $151.0 million in 2022, then fell by 11.26% to $134.0 million in 2023, then soared by 65.67% to $222.0 million in 2024, then fell by 0.9% to $220.0 million in 2025, then grew by 0.45% to $221.0 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $221.0 million in Q2 2026, $219.0 million in Q1 2026, and $220.0 million in Q4 2025.